Article Data

  • Views 722
  • Dowloads 149

Original Research

Open Access

Use of 7.5 mg/kg of bevacizumab to palliate symptomatic malignant ascites in recurrent ovarian cancer

  • Y. Shimizu1
  • T. Nakanishi1,*,
  • K. Sasamoto1
  • S. Kondo1

1Department of Gynecology, Aichi Cancer Center Hospital, Nagoya City, Japan

DOI: 10.12892/ejgo3776.2018 Vol.39,Issue 3,June 2018 pp.404-407

Published: 10 June 2018

*Corresponding Author(s): T. Nakanishi E-mail: trnakans@yahoo.co.jp

Abstract

Purpose: To investigate the effectiveness of single-agent intravenous bevacizumab (7.5 mg/kg every three to four weeks) for palliating symptomatic malignant ascites caused by recurrent ovarian cancer, the authors examined the cases retrospectively. Materials and Methods: Five patients with recurrent ovarian cancer and malignant ascites were treated with bevacizumab. Results: A total of 23 bevacizumab infusions were administered for the patients, and the mean inter-infusion interval was 26.1 days (range: 21-35). After one course of therapy, no further paracentesis was required in four patients. However, bevacizumab was not effective in one patient and hence paracentesis had to be repeated. Due to disease progression, treatment was aborted in four patients, who died of their disease within a few months of the bevacizumab treatment (median overall survival period: 3.3 months). Conclusion: The intravenous infusion of 7.5 mg/kg bevacizumab at three- to four-week intervals is a promising therapy for malignant ascites caused by recurrent ovarian cancer.

Keywords

Bevacizumab; Malignant ascites; Ovarian cancer.

Cite and Share

Y. Shimizu,T. Nakanishi,K. Sasamoto,S. Kondo. Use of 7.5 mg/kg of bevacizumab to palliate symptomatic malignant ascites in recurrent ovarian cancer. European Journal of Gynaecological Oncology. 2018. 39(3);404-407.

References

[1] Kobold S., Hegewisch-Becker S., Oechsle K., Jordan K., Bokemeyer C., Atanackovic D.: “Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?” Oncologist, 2009,14,1242.

[2] Togami S., Hori S., Kamio M., Matsuo T., Yoshinaga M., Douchi T.: “Clinical usefulness of concentrated ascites reinfusion therapy (CART) for gynecological cancer patients with refractory massive ascites due to cancerous peritonitis”. Eur. J. Gynaecol. Oncol., 2014, 35, 301.

[3] Monk B.J., Pujade-Lauraine E., Burger R.A.: “Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease”. Ann. Oncol., 2013, 24, x53.

[4] Numnum T.M., Rocconi R.P., Whitworth J., Barnes M.N.: “The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma”. Gynecol. Oncol., 2006, 102, 425.

[5] Kesterson J.P., Mhawech-Fauceglia P., Lele S.: “The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report”. Gynecol. Oncol., 2008, 111, 527.

[6] Bellati F., Napoletano C., Ruscito I., Pastore M., Pernice M., Antonilli M., et al.: “Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review”. Invest. New Drugs, 2010, 28, 887.

[7] Cannistra S.A., Matulonis U.A., Penson R.T., Hambleton J., Dupont J., Mackey H., et al.: “Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer”. J. Clin. Oncol., 2007, 25, 5180.

[8] Rustin G.J., Quinn M., Thigpen T., du Bois A., Pujade-Lauraine E., Jakobsen A., et al.: “Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)”. J. Natl. Cancer Inst., 2004, 96, 487. 406

[9] Heiss M.M., Murawa P., Koralewski P., Kutarska E., Kolesnik O.O., Ivanchenko V.V., et al.: “The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial”. Int. J. Cancer, 2010, 127, 2209.

[10] Gotlieb W.H., Amant F., Advani S., Goswami C., Hirte H., Provencher D., et al.: “Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study”. Lancet Oncol., 2012, 13, 154.

[11] Mehta D.A., Hay J.W.: “Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer”. Gynecol. Oncol., 2014, 132, 677.

[12] Cohn D.E., Barnett J.C., Wenzel L., Monk B.J., Burger R.A., Straughn J.M. Jr., et al.: “A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer”. Gynecol. Oncol., 2015, 136, 293.

[13] Emile G., Chauvenet L., Tigaud J.M., Chidiac J., Pujade Lauraine E., Alexandre J.: “A clinical experience of single agent bevacizumab in relapsing ovarian cancer”. Gynecol. Oncol., 2013, 129, 459.

[14] Liu Y., Ren Z., Xu S., Bai H., Ma N., Wang F.: “Low-doseintensity bevacizumab with weekly irinotecan for platinum- and taxanes- resistant epithelial ovarian cancer”. Cancer Chemother. Pharmacol., 2015, 75, 645.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top